Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 4Recruiting 3Active not recruiting 2Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma 1

Interventions

Cyclophosphamide 4Prednisone 3Lenalidomide 3fludarabine phosphate 2etoposide phosphate 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Stem Cell Transplantation 2Nivolumab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Doxorubicin 2Bortezomib 2Alemtuzumab 2tazemetostat 1sargramostim 1romidepsin 1poly ICLC 1plerixafor 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1pegaspargase 1liposomal doxorubicin 1forodesine 1fludarabine 1duvelisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, T-Cell × 10-propargyl-10-deazaaminopterin × Clear all
NCT01420679 2021-11-19

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

Spectrum Pharmaceuticals, Inc

Phase 3 Terminated
21 enrolled 8 charts
Lymphoid

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡